SLC38A3 and type 2 diabetes mellitus: Conversely, when plasma levels of glutamine are low it is released by SLC38A3 and taken up by α-cells inducing the release of glucagon and the increase of hepatic gluconeogenesis [32,33], a process substantially increased in patients with T2D [34].